AVXL
ANAVEX LIFE SCIENCES CORP.Company Information
- Company Name
- ANAVEX LIFE SCIENCES CORP.
- CIK
- CIK0001314052
- Category
- Large accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- AVXL: Nasdaq
- Fiscal Year End
- September 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- AVXL
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-06-14
- Last sale
- 2024-03-28
- Shares purchased (TTM)
- 7,835
- Shares sold (TTM)
- 341,380
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 37,422,712
- Shares outstanding
- 92,696,842
- Ownership
- 40.37%
Earnings Market Reaction
- Filing date
- 2026-08-28
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 118 | 127 | 132 | 103 | 101 | 116 | 121 | 132 | 139 | 139 | 144 | 151 | ||||||
| Income Taxes Receivable | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 2 | 4 | 4 | 3 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 120 | 129 | 133 | 104 | 102 | 117 | 124 | 136 | 142 | 145 | 148 | 154 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 3 | 3 | 4 | 7 | 7 | 5 | 10 | 4 | 4 | 4 | 4 | ||||||
| Accrued Liabilities Current | 4 | 4 | 3 | 4 | 4 | 10 | 8 | 5 | 7 | 5 | 7 | 7 | ||||||
| Deferred Income Current | - | - | - | - | 1 | 1 | 1 | - | 1 | 1 | 1 | - | ||||||
| Deferred Rent Credit | - | 1 | 1 | 1 | - | - | - | 1 | - | - | - | 1 | ||||||
| Liabilities | 8 | 7 | 6 | 9 | 11 | 17 | 13 | 15 | 12 | 10 | 12 | 13 | ||||||
| Preferred Stock Value | - | - | - | - | 0 | - | - | - | - | 0 | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 498 | 515 | 515 | 477 | 463 | 459 | 459 | 456 | 454 | 447 | 437 | 435 | ||||||
| Retained Earnings Accumulated Deficit | -386 | -393 | -388 | -382 | -373 | -359 | -348 | -336 | -324 | -312 | -302 | -293 | ||||||
| Stockholders Equity | 112 | 122 | 127 | 95 | 91 | 100 | 111 | 120 | 130 | 135 | 136 | 142 | ||||||
| Liabilities And Stockholders Equity | 120 | 129 | 133 | 104 | 102 | 117 | 124 | 136 | 142 | 145 | 148 | 154 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Issued | 93 | 93 | 93 | 87 | 85 | 85 | 85 | 85 | 85 | 84 | 82 | 82 | ||||||
| Shares Outstanding | 93 | 93 | 93 | 87 | 85 | 85 | 85 | 85 | 85 | 84 | 82 | 82 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialANAVEX LIFE SCIENCES CORP. (AVXL) — SEC Financial Statements & Analysis
ANAVEX LIFE SCIENCES CORP. (AVXL) is a biological products, (no diagnostic substances) company. ANAVEX LIFE SCIENCES CORP. trades on Nasdaq as: AVXL. ANAVEX LIFE SCIENCES CORP. (AVXL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-28. Based on that filing, ANAVEX LIFE SCIENCES CORP. carries a market cap of $240.08M, a P/E ratio of -18.44x, a P/B ratio of 2.14x, an enterprise value of $121.76M, and an EV/EBITDA multiple of -7.01x. On profitability, it posts a Return on Equity (ROE) of -12.80%. Per share, it reports EPS of $-0.14, diluted EPS of $-0.14, free cash flow per share of $-0.32, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -72.97% year-over-year and EPS growth of -75.10% year-over-year. On the balance sheet, it maintains an interest coverage ratio of -4.13x, free cash flow of $-29.29M (TTM), and net debt of $-118.33M. Figures sourced from SEC EDGAR.
- Market Cap
- $240.08M
- P/E TTM
- -18.44x
- EPS TTM
- $-0.14
- P/B TTM
- 2.14x
- ROE TTM
- -12.80%
- Free Cash Flow TTM
- $-29.29M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ANAVEX LIFE SCIENCES CORP. in?
ANAVEX LIFE SCIENCES CORP. (AVXL) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does AVXL trade on?
ANAVEX LIFE SCIENCES CORP. (AVXL) trades on the Nasdaq.
When was ANAVEX LIFE SCIENCES CORP. (AVXL)'s most recent SEC filing?
ANAVEX LIFE SCIENCES CORP. (AVXL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-28.
What is AVXL's market cap?
ANAVEX LIFE SCIENCES CORP. (AVXL) has a market capitalization of $240.08M as of 2026-06-30.
What is AVXL's EPS (earnings per share)?
ANAVEX LIFE SCIENCES CORP. (AVXL)'s trailing twelve month EPS is $-0.14 as of 2026-06-30.
What is AVXL's ROE (return on equity)?
ANAVEX LIFE SCIENCES CORP. (AVXL)'s trailing twelve month Return on Equity (ROE) is -12.80% as of 2026-06-30.
What is AVXL's EV/EBITDA?
ANAVEX LIFE SCIENCES CORP. (AVXL)'s trailing twelve month EV/EBITDA is -7.01x as of 2026-06-30.